PT1362600E - Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica - Google Patents

Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica Download PDF

Info

Publication number
PT1362600E
PT1362600E PT02711351T PT02711351T PT1362600E PT 1362600 E PT1362600 E PT 1362600E PT 02711351 T PT02711351 T PT 02711351T PT 02711351 T PT02711351 T PT 02711351T PT 1362600 E PT1362600 E PT 1362600E
Authority
PT
Portugal
Prior art keywords
decoy
decoys
stat
atopic dermatitis
topical use
Prior art date
Application number
PT02711351T
Other languages
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Publication of PT1362600E publication Critical patent/PT1362600E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT02711351T 2001-02-20 2002-02-06 Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica PT1362600E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20

Publications (1)

Publication Number Publication Date
PT1362600E true PT1362600E (pt) 2008-07-09

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02711351T PT1362600E (pt) 2001-02-20 2002-02-06 Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica

Country Status (11)

Country Link
US (2) US9012417B2 (pt)
EP (2) EP1362600B1 (pt)
JP (2) JP3778357B2 (pt)
AT (1) ATE390938T1 (pt)
CY (1) CY1108165T1 (pt)
DE (1) DE60225899T2 (pt)
DK (1) DK1362600T3 (pt)
ES (1) ES2307733T3 (pt)
PT (1) PT1362600E (pt)
TW (1) TWI308492B (pt)
WO (1) WO2002066070A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732929B1 (en) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US9012417B2 (en) * 2001-02-20 2015-04-21 Anges Mg, Inc. Topical administration of NF-kappaB decoy to treat atopic dermatitis
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
CN1784248B (zh) * 2003-05-09 2010-11-10 森下龙一 收容药剂的无针注射器
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
EP1691817A2 (en) * 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
US7927873B2 (en) * 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
US20060069055A1 (en) * 2004-09-21 2006-03-30 Maya Dajee Delivery of polynucleotides
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
CA2614295A1 (en) 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
JP2009502913A (ja) * 2005-07-27 2009-01-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 調節因子
CA2634291A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
EP2127681A4 (en) 2007-02-16 2011-10-12 Anges Mg Inc THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
WO2008141308A2 (en) 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
US20110092438A1 (en) * 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
RU2017108238A (ru) 2014-08-15 2018-09-17 Эйдинкс, Инк. Олигонуклеотиды-приманки для лечения боли

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
EP0732929B1 (en) 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0793963A4 (en) * 1994-10-24 2001-12-12 Nikken Chemicals Co Ltd PREPARABLE TRANSDERMAL PREPARATION
DK0824918T3 (da) * 1995-05-12 2007-06-04 Anges Mg Inc Behandling og forebyggelse af sygdomme forårsaget af NF-kappa B
CZ154898A3 (cs) * 1995-11-21 1998-09-16 Icn Pharmaceuticals, Inc. Oligonukleotidy pro inhibici růstu nádorů zprostředkovaných IL-8 a receptorem IL-8
JP2002510319A (ja) * 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
JP2001055331A (ja) 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
WO2001057204A1 (fr) * 2000-02-02 2001-08-09 Yasufumi Kaneda Vecteur d'enveloppe virale pour transfert de gene
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
US9012417B2 (en) 2001-02-20 2015-04-21 Anges Mg, Inc. Topical administration of NF-kappaB decoy to treat atopic dermatitis
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
JPWO2002066070A1 (ja) 2004-06-17
JP3778357B2 (ja) 2006-05-24
US20090105183A1 (en) 2009-04-23
EP1362600B1 (en) 2008-04-02
TWI308492B (pt) 2009-04-11
EP1690544B1 (en) 2017-09-13
DK1362600T3 (da) 2008-07-28
US20040162251A1 (en) 2004-08-19
DE60225899T2 (de) 2009-04-09
EP1690544A3 (en) 2012-03-07
JP4987022B2 (ja) 2012-07-25
EP1690544A2 (en) 2006-08-16
US9012417B2 (en) 2015-04-21
WO2002066070A1 (fr) 2002-08-29
EP1362600A4 (en) 2005-09-21
CY1108165T1 (el) 2014-02-12
JP2009102428A (ja) 2009-05-14
DE60225899D1 (de) 2008-05-15
ES2307733T3 (es) 2008-12-01
EP1362600A1 (en) 2003-11-19
ATE390938T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
PT1362600E (pt) Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
MXPA05002791A (es) Oligonucleotidos antivirales complementarios sin secuencia.
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2001042457A3 (en) Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2001081671A3 (en) Methods and fabrics for combating nosocomial infections
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
HK1130422A1 (en) A new use of deferiprone
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
WO1999041364A3 (en) Compositions and methods for wound healing
WO2003099213A3 (en) Method for reducing platelet count
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
AU3290200A (en) Treatment agents for textiles, method of producing same and their use
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
AU2003222326A1 (en) Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases
WO2000050023A8 (en) Use of tamoxifen and related compounds as clc3 blockers in the treatment of vascular diseases